Weedkiller 'raises risk of non-Hodgkin lymphoma by 41%'
Study says evidence ‘supports link’ between exposure to glyphosate and increased riskSign up for the US morning briefing for a fresh perspectiveA broadnew scientific analysis of the cancer-causing potential of glyphosate herbicides, the most widely used weedkilling products in the world, has found that people with high exposures to the popular pesticides have a 41% increased risk of developing a type of cancer called non-Hodgkin lymphoma.The evidence “supports a compelling link” between exposures to glyphosate-based herbicides and increased risk for non-Hodgkin lymphoma (NHL), the authors concluded, though they sai...
Source: Guardian Unlimited Science - February 14, 2019 Category: Science Authors: Carey Gillam Tags: Monsanto Agriculture Science Business Cancer Herbicides Environment Health Source Type: news
Weedkiller chemical increases the risk of cancer 'by up to 41 per cent', study finds
Researchers led by the University of California Berkeley have said high exposure to the weedkiller glyphosate could cause non-Hodgkin lymphoma cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - February 14, 2019 Category: Consumer Health News Source Type: news
Exposure to weed killing products increases risk of cancer by 41% – study
Evidence ‘supports link’ between exposures to glyphosate herbicides and increased risk for non-Hodgkin lymphomaA broadnew scientific analysis of the cancer-causing potential of glyphosate herbicides, the most widely used weed killing products in the world, has found that people with high exposures to the popular pesticides have a 41% increased risk of developing a type of cancer called non-Hodgkin lymphoma.The evidence “supports a compelling link” between exposures to glyphosate-based herbicides and increased risk for non-Hodgkin lymphoma (NHL), the authors concluded, though they said the specific numerical risk es...
Source: Guardian Unlimited Science - February 14, 2019 Category: Science Authors: Carey Gillam Tags: Monsanto Agriculture Science Business Cancer Herbicides Environment Health Source Type: news
Glyphosate MDL Plaintiffs Present Exhibit About Monsanto's Lack Of Testing
SAN FRANCISCO - The plaintiffs in the multidistrict litigation for the herbicide Roundup on Jan. 25 filed exhibits in California federal court that are documents from a separate glyphosate case in which Monsanto Co. admits that it has not conducted a study specifically designed to examine if an association exists between glyphosate exposure and non-Hodgkin lymphoma (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 5, 2019 Category: Medical Law Source Type: news
Medical News Today: Everything you need to know about R-CHOP
R-CHOP chemotherapy uses a combination of five different drugs to treat specific types of cancer, including non-Hodgkin lymphoma. Learn more about how this treatment works and the potential side effects here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 23, 2019 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Cerebellar Large B-cell Lymphoma: A Case Report Cerebellar Large B-cell Lymphoma: A Case Report
This case report reviews the diagnosis, pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Allergan Halts Sales in Europe of Textured Breast Implants Linked to Rare Cancer
The company ’ s product, in use worldwide, has been under scrutiny since women began developing a type of lymphoma. (Source: NYT Health)
Source: NYT Health - December 19, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Medical Devices Plastic Surgery Non-Hodgkin's Lymphoma France Allergan Inc Cancer Recalls and Bans of Products Europe Source Type: news
Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Medical News Today: Does HIV increase cancer risk?
HIV can weaken a person ’s immune system, which can increase the risk of certain types of cancer. Such cancers include Kaposi’s sarcoma, non-Hodgkin lymphoma, and cervical, lung, anal, and oral cancer. However, effective treatment can significantly reduce the risk of developing these cancers. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news
ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
MONDAY, Dec. 3, 2018 -- For heavily pretreated patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL), response rates are high for treatment subsequent to checkpoint blockade therapy (CBT), according to two... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news
Genetically engineered immune cells show promise for fighting relapsed blood cancer
(UNC Lineberger Comprehensive Cancer Center) At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger Comprehensive Cancer Center researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news
Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma
(University of Pennsylvania School of Medicine) In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah ® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news
Non-Hodgkin Lymphoma | Medscape Non-Hodgkin Lymphoma | Medscape
Non-Hodgkin lymphoma is the fifth most common cancer in the United States, accounting for about 4% of all malignancies in both men and women. The disease comprises a variety of cancers of the lymphatic system exclusive of Hodgkin lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news
Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
Title: Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma DrugCategory: Health NewsCreated: 11/28/2018 12:00:00 AMLast Editorial Review: 11/29/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 29, 2018 Category: Cancer & Oncology Source Type: news
FDA approves first biosimilar to Roche cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
